A J Kraker
Overview
Explore the profile of A J Kraker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kraker A, Petering D
Biol Trace Elem Res
. 2013 Nov;
5(4-5):363-74.
PMID: 24263573
Features of tumor and host zinc metabolism are described. Emphasis is placed on tumor-host interactions. Using the model of the Ehrlich ascites tumor in mice, one clear site of modulation...
2.
DORSEY J, Cunnick J, Lanehart R, Huang M, Kraker A, Bhalla K, et al.
Leukemia
. 2002 Aug;
16(9):1589-95.
PMID: 12200668
Bcr-Abl tyrosine kinase has been validated as a molecular target for the treatment of chronic myelogenous leukemia (CML). More recently, it has been reported that CML patients could develop resistance...
3.
Schroeder M, Hamby J, CONNOLLY C, Grohar P, Winters R, Barvian M, et al.
J Med Chem
. 2001 Jun;
44(12):1915-26.
PMID: 11384237
In continuing our search for medicinal agents to treat proliferative diseases, we have discovered 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas as a novel class of soluble, potent, broadly active tyrosine kinase (TK) inhibitors....
4.
Thompson A, CONNOLLY C, Hamby J, Boushelle S, Hartl B, Amar A, et al.
J Med Chem
. 2000 Nov;
43(22):4200-11.
PMID: 11063616
A series of 3-aryl-1,6-naphthyridine-2,7-diamines and related 2-ureas were prepared and evaluated as inhibitors of the FGF receptor-1 tyrosine kinase. Condensation of 4,6-diaminonicotinaldehyde and substituted phenylacetonitriles gave intermediate naphthyridine-2,7-diamines, and direct...
5.
Kraker A, Hartl B, Amar A, Barvian M, Showalter H, Moore C
Biochem Pharmacol
. 2000 Sep;
60(7):885-98.
PMID: 10974196
Increased expression or activity of c-Src tyrosine kinase has been associated with the transformed phenotype in tumor cells and with progression of neoplastic disease. A number of pyrido[2, 3-d]pyrimidines have...
6.
Thompson A, Rewcastle G, Boushelle S, Hartl B, Kraker A, Lu G, et al.
J Med Chem
. 2000 Aug;
43(16):3134-47.
PMID: 10956222
7-substituted 3-(2,6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones are potent inhibitors of protein tyrosine kinases, with some selectivity for c-Src. The compounds were prepared by condensing 4, 6-diaminonicotinaldehyde with 2,6-dichlorophenylacetonitrile and selectively converting the 2- and...
7.
DORSEY J, Jove R, Kraker A, Wu J
Cancer Res
. 2000 Jun;
60(12):3127-31.
PMID: 10866298
PD180970 is a novel pyrido[2,3-d]pyrimidine class of ATP-competitive inhibitor of protein tyrosine kinases. We found that PD180970 inhibited in vivo tyrosine phosphorylation of p210Bcr-Abl (IC50 = 170 nM) and the...
8.
Moasser M, Srethapakdi M, Sachar K, Kraker A, Rosen N
Cancer Res
. 2000 Jan;
59(24):6145-52.
PMID: 10626805
src kinase activity is elevated in some human tumors, including breast and colon cancers. The precise cellular function of the src family kinases is not clearly understood, but they appear...
9.
Palmer B, Kraker A, Hartl B, Panopoulos A, Panek R, Batley B, et al.
J Med Chem
. 1999 Jul;
42(13):2373-82.
PMID: 10395478
Following an earlier discovery of 1-phenylbenzimidazoles as ATP-site inhibitors of the platelet-derived growth factor receptor (PDGFR), further structure-activity relationships for analogues (particularly 5-substituted derivatives) are reported. The data are consistent...
10.
Allgayer H, Wang H, Gallick G, Crabtree A, Mazar A, Jones T, et al.
J Biol Chem
. 1999 Jun;
274(26):18428-37.
PMID: 10373450
Since c-src overexpression increases colonic cell invasiveness and because both Src activity and urokinase receptor protein are elevated in invasive colon cancers, the present study was undertaken: 1) to determine...